eligibility_summary
Include: Age 0.5–18 with hematologic malignancy (post‑allo HSCT relapse: AML/ALL/JMML, refractory ALL/AML, high‑risk infant ALL), no better curative option, KPS ≥50 or Lansky ≥30, parental consent, able to comply, adequate cardiac/organ function, ≥2 weeks since chemo and recovered, HAMA‑negative. Exclude: HAMA‑positive, organ dysfunction, isolated CNS relapse, active serious infection, pregnancy/lactation or no contraception, severe comorbidity, extensive cGVHD, unstable CVD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT04856215. Intervention: 90Yttrium-labelled anti-CD66 monoclonal antibody (BW250/183), a murine IgG1 radioimmunoconjugate, preceded by 111Indium-labelled anti-CD66 for imaging/dosimetry. Mechanism of action: Radioimmunotherapy—antibody binds CD66 (CEACAM antigens, notably on granulocytes/myeloid cells) to concentrate a beta-emitting radionuclide (90Y) in bone marrow and spleen, delivering localized radiation that induces DNA damage and cytotoxicity to eradicate leukemic cells while sparing other organs. Drug type: Radiolabeled monoclonal antibody (theranostic pair: 111In for dosimetry, 90Y for therapy). Target cells/pathways: CD66+ myeloid/granulocytic elements within bone marrow and spleen, indirectly targeting leukemic blasts residing in these compartments, effect is marrow-directed myeloablation prior to allogeneic HSCT.